title: Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma.
authors.affiliation: Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany. paul.larosee@med.uni-jena.de
authors.forename: Friederike
authors.initials: F
authors.lastname: Hunstig
authors.forename: Jakob
authors.initials: J
authors.lastname: Hammersen
authors.forename: Christa
authors.initials: C
authors.lastname: Kunert
authors.forename: Iver
authors.initials: I
authors.lastname: Petersen
authors.forename: Hartmut
authors.initials: H
authors.lastname: Merz
authors.forename: Anita
authors.initials: A
authors.lastname: Glaser
authors.forename: Ulf
authors.initials: U
authors.lastname: Teichgräber
authors.forename: Andreas
authors.initials: A
authors.lastname: Hochhaus
authors.forename: Paul
authors.initials: P
authors.lastname: La Rosée
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20 / Q000187:drug effects*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D005434:Flow Cytometry; D006801:Humans; D060828:Induction Chemotherapy; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000187:drug effects / Q000235:genetics*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C529133:IGH-CCND1 fusion protein, human; D015514:Oncogene Proteins, Fusion; C527517:ofatumumab